Thank you, Dr. Sereda.
Safe supply and supervised consumption sites clearly emerged in response to overdoses, the opioid crisis and fentanyl contamination in drugs.
Safe supply, however, has given rise to another problem: the diversion of prescribed safe supply drugs. I want to give you a chance to share your thoughts on the problem. I'd like you to discuss that and tell us whether it's something we need to deal with, given what you've seen in the last year. What should we be doing? Enlighten us, if you would.
Dr. Sereda, you can go first since you didn't get a chance to finish what you were saying about that earlier.
Mr. Letellier de St‑Just, you can go next.